-

DrFirst Names Laizer Kornwasser as Chief Executive Officer

G. Cameron Deemer to continue serving as vice chairman of the board of directors

ARLINGTON, Va.--(BUSINESS WIRE)--Healthcare technology pioneer DrFirst announced today that Laizer Kornwasser, a transformative healthcare executive with a track record of driving rapid growth, has been named chief executive officer, effective July 21, 2025. G. Cameron Deemer, who has served as CEO since 2023 and president for 15 years, will continue to support the company’s strategic initiatives as vice chairman of the board of directors.

This planned succession reinforces DrFirst’s commitment to innovation and growth, building on 25 years of healthcare technology leadership. Today, the company develops end-to-end medication management solutions that reach over 100 million patients annually through integrations and partnerships with electronic systems used by hospitals, medical practices, and pharmacies nationwide.

Kornwasser brings over two decades of healthcare leadership experience across pharmacy, telemedicine, chronic care, pharmaceutical companies, and PBMs. Most recently, he served as president of enterprise growth and emerging markets at Teladoc Health. He previously held senior executive roles at CareCentrix and Medco Health. Kornwasser holds an MBA from Harvard Business School and has served as a professor at Yeshiva University’s Sy Syms School of Business.

“What drew me to this company is its consistent ability to identify gaps in medication management and create effective solutions to close those gaps, while maintaining an unwavering commitment to customers and employees,” said Kornwasser. “DrFirst has built something extraordinary—patented AI technologies, the nation’s largest medication management network, and deep integration with virtually every major EHR system. I’m excited to lead this exceptional team as we accelerate our strategy and continue to deliver comprehensive, interoperable solutions.”

Market-leading portfolio

Under founder James Chen’s and Deemer’s leadership, DrFirst established first-to-market innovations now used industry-wide, including:

  • Electronic prescribing for controlled substances (EPCS)
  • Real-time prescription benefit checks
  • Patented AI for interoperability
  • Prescription orchestration technology

“As we prepared for DrFirst’s next growth phase, we were seeking a leader who could embrace our vision and scale our market-leading platform,” said Deemer. “Laizer’s proven ability to drive aggressive growth while building cultures that attract and retain top talent makes him ideal to lead DrFirst going forward.”

Chen, who founded DrFirst in 2000 and led the company through its emergence as a healthcare technology leader, now serves as executive chairman of the board. He added, “Laizer’s extraordinary track record of business transformation and operational excellence across multiple healthcare sectors aligns perfectly with our vision for the company’s future. His leadership will be instrumental as we pursue rapid growth.”

Industry recognition validates market position

The company was recently honored to receive Frost & Sullivan’s 2025 Enabling Technology Leadership Recognition, which noted, “With a record of continuous innovation and strategic expansion, DrFirst is well-positioned as a key player in the healthcare industry, fostering collaboration and optimizing care at every stage of the patient journey.”

In recent years, the company has won over 25 awards for excellence, including Gold in the prestigious Edison Awards for its clinical-grade AI that streamlines healthcare workflows and prevents medication errors.

About DrFirst

For 25 years, healthcare IT pioneer DrFirst has empowered providers and patients to achieve better health through intelligent medication management. We improve healthcare workflows and help patients start and stay on therapy with end-to-end solutions that enhance prescription access, affordability, and adherence. Our solutions help 100 million patients a year and are used by more than 450,000 prescribers, 71,000 pharmacies, 270 EHRs and health information systems, and over 2,000 hospitals in the U.S. To learn more, visit DrFirst.com.

Contacts

MEDIA CONTACT
Erin Jundef, Bospar Communications
erin@bospar.com

DrFirst


Release Versions

Contacts

MEDIA CONTACT
Erin Jundef, Bospar Communications
erin@bospar.com

More News From DrFirst

First-of-its-Kind Integrated, Secure Dialing Extends the Power of Mobile E-Prescribing for Healthcare Providers

ROCKVILLE, Md.--(BUSINESS WIRE)--iPrescribe by DrFirst announces the launch of Connect, the first integrated dialer that lets prescribers make secure and private calls with patients and others. Calls made through the app display the practice’s designated office number, maintaining professional boundaries and presenting patients with a number they are likely to recognize and trust. This innovation simplifies secure patient communication, allowing providers to make calls within the prescribing wo...

TrueRx: AI-Powered Monitoring and Alert System Is the Industry’s First Prescription for Fraud

ROCKVILLE, Md.--(BUSINESS WIRE)--DrFirst’s new prescription monitoring solution – TrueRx – will give the nation’s pharmacies their first-ever standardized alert system to protect against prescriber identity and prescription fraud. Backed by AI-enabled digital fingerprint technology, the health tech pioneer’s latest, patent-pending innovation shores up a longstanding point of vulnerability: the risk of a prescriber’s identity information being used by bad actors to gain access to medical credent...

More Than a Third of Americans Report Not Taking Medication as Prescribed Amid Economic Struggles

ROCKVILLE, Md.--(BUSINESS WIRE)--Over a third of Americans (35%) report making hard – sometimes dangerous – compromises in recent months if they can’t afford their prescription medication, according to new research by iPrescribe, the mobile e-prescribing app by health technology pioneer DrFirst. The survey of 1,023 consumers explores how the economy is affecting people’s ability to afford their medications and healthcare. “It's troubling that one in three people tell us they’ve stopped taking t...
Back to Newsroom